Search company, investor...

Founded Year



Other Investors | Alive

About Bionas

Bionas specializes in analyzing systems for in vitro profiling the metabolic activity of cells with special respect to cellular bioenergetics, adhesion and morphology.

Headquarters Location

Friedrich-Barnewitz-Straße 3





Latest Bionas News

Katsina, Malaysian firm sign agreement on battling desertification in 11 LGAs

Oct 13, 2021

The Katsina Government has signed a Memorandum of Understanding (MoU) with a Malaysia-based firm, Bionas, under which 199 million dollars would be spent to battle desertification in the state, according to News Agency of Nigeria. Speaking at the signing of the MoU on Tuesday in Katsina, Gov. Aminu Masari said the money would be used […]

Bionas Frequently Asked Questions (FAQ)

  • When was Bionas founded?

    Bionas was founded in 2001.

  • What is Bionas's latest funding round?

    Bionas's latest funding round is Other Investors.

  • Who are the investors of Bionas?

    Investors of Bionas include ERP-Startfonds, GENIUS Venture Capital and KfW.

  • Who are Bionas's competitors?

    Competitors of Bionas include Entegrion, Cognate BioServices, Biomatrica, Lipomics Technologies, CytoSolv and 7 more.


Compare Bionas to Competitors

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company focused on providing business intelligence in the pharmaceutical and biologic drugs sector. The company's main services include offering insights on life cycle management, brand erosion, generic entry, biosimilars, patents, sales, litigation, and more, all related to pharmaceutical and biologic drugs. The company primarily serves the biopharmaceutical industry. It is based in Troy, New York.

Core Dynamics

Core Dynamics is a development-stage company focused on the freezing and lyophilization of white blood cells and stem cells and their preservation and storage at room temperature.


NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).

Salzburg Therapeutics

Salzburg Therapeutics is a drug development company that is developing Cytotoxamer and Genotoxamer products for cancer treatment. The company's technology aims to provide a solution for delivering activated forms of anticancer drugs, nanoparticles, and other moieties specifically to cancer cells.


InvivoSciences is a precision medicine company operating in the drug development and life sciences research sectors. The company's main offerings include the development of patient-derived and gene-edited human samples, specifically functional 3D engineered micro-human heart tissue platforms, which are used to personalize the drug development process. These platforms, combined with the company's integration of cell and tissue handling automation, tissue phenotyping assays, and computational biology, enable the rapid identification of safety and efficacy profiles of treatments for specific patient groups. It was founded in 2001 and is based in Wauwatosa, Wisconsin.

Novacta Biosystems

Aiming to leverage the knowledge of GSK's Biotransformation and Natural Products scientific team, Novacta Biosystems Ltd was founded in 2003. In the following 5 years, Novacta successfully adopted a dual business model, whereby it developed a biocatalysis and microbial pathway engineering service business, that supported its efforts to build an infectious disease therapeutic pipeline.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.